Pharma BD Deal Intelligence
GSK's $3B acquisition of Human Genome Sciences gave it full control of Benlysta, the lupus drug the two companies already co-owned—ending a profit-split structure rather than launching something new. A modest win: the deal consolidated GSK's autoimmune franchise, though it came years after Benlysta's underwhelming initial launch.
GSK acquired Human Genome Sciences for $3B for lupus and diabetes treatments.
GSK finalized its Human Genome Sciences acquisition for $14.25 per share in cash, completing a deal that brings Benlysta royalty savings and an expanded…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
GSK acquired Human Genome Sciences for $3B for lupus and diabetes treatments.
16K US cases/yr · $1.5B Global SLE Therapeutics Market (2013)
Systemic lupus erythematosus is a chronic autoimmune disease affecting multiple organ systems. Before Benlysta's approval in 2011, no new drug had been approved for SLE in over 50 years. Treatment relied on corticosteroids, antimalarials, and immunosuppressants. Benlysta (belimumab) was the first targeted biologic for SLE.
Benlysta was the only FDA-approved biologic for SLE at the time of acquisition. Competition was limited to generic immunosuppressants and off-label rituximab. GSK's $3B acquisition of HGS gave them full ownership of Benlysta (previously co-developed). The drug has since expanded to lupus nephritis (2020) and grown to $2.6B in 2024 sales, vindicating the acquisition despite initial slow uptake.
GSK completed $3B acquisition of Human Genome Sciences, gaining full control of Benlysta (belimumab) for systemic lupus erythematosus.
FDA approved Benlysta for lupus nephritis, first drug approved for this indication, significantly expanding the addressable patient population.
Benlysta achieved approximately $2.5B in annual sales driven by lupus nephritis expansion and growing SLE penetration globally.
Benlysta grew from ~$300M at deal close to $2.5B+ annually. The $3B acquisition delivered exceptional long-term returns, one of GSK's best deals.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Human Genome Sciences (this deal) | 2012 | $3.6B | 70 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2012 deals · GSK plc deals · Immunology deals